OBJECTIVE: Chemoresistance to cisplatin significantly contributes to treatment failure in clinical management of head and neck cancer. Our preclinical and clinical studies have demonstrated that enhanced DNA repair by MRE11/RAD50/NBS1 (MRN) complex is a critical molecular mechanism for cisplatin-based chemoresistance. The poly (ADP-ribose) polymerase 1 (PARP 1) is involved in the DNA repair pathway and is activated in response to DNA damaging agents. This study further investigates the signaling pathways of MRN complex and PARP1 in response to cisplatin-based chemoresistance for the treatment of human head and neck squamous cell carcinoma (HNSCC). METHOD: Two human HNSCC cell lines, JHU006 and JHU020, were used. JHU006 has been previously characterized as a cisplatin-resistant tumor cell line. Clinical data and tumor samples of patients with HNSCC initially treated with cisplatin monotherapy were reviewed and immunohistochemically investigated, respectively. The MRN and PARP1 expressions after cisplatin treatment were evaluated using real time RT-PCR and immunohistochemistry. The relationship between MRN and PARP1 in regulating the DNA repair system was investigated. RESULTS: Wild-type PARP1 was found in the tumor cells studied. An increased level of PARP1 expression was detected in cisplatin-resistant tumors and correlated with the MRN expression profile. Although inhibition of MRN expression could sensitize tumor cells to cisplatin resistant, it did not affect PARP1 expression. CONCLUSION: The current study suggests that increased expression level of PARP1 after cisplatin treatment is associated with a cisplatin-resistant phenotype. Inhibition of both PARP1 and MRN may improve the treatment outcomes in human HNSCC complicated with cisplatin chemoresistance.
Traumatic Airway Management in Operation Iraqi Freedom (OIF)
Joseph Brennan, MD (presenter); Mark Gibbons, MD; Manuel Lopez, MD; Robert Eller, MD; Chester Barton, MD OBJECTIVE: 1) Examine the role of otolaryngologists in traumatic airway management in OIF. 2) Determine the presenting signs and symptoms of and define the surgical indications for traumatic airway management. 3) Understand the lessons learned in traumatic airway management to include a simple airway triage classification which will guide surgical management.
METHOD:
The surgical airway experience of six otolaryngologists deployed over a 30 month period in Iraq was retro-spectively reviewed. The clinical indications, airway interventions, and outcomes of patients requiring surgical airways were determined. A simple classification for traumatic airway injuries using a military trauma color classification (red, yellow, green) will be proposed. RESULTS: One hundred and ninety-four surgical airway procedures were performed in OIF over 30 months. Red or emergent surgical airways were performed in 7% (13/194) of cases, yellow or delayed surgical airways were performed in 25% (48/194) of cases, and green or elective surgical airways were performed in 68% (133/194) of cases. Life-saving surgical airways (red/yellow airways) were performed in 32% (61/194) of patients requiring a surgical airway. Surgical repair of the laryngotracheal complex was performed in 29 patients to include 18 thyroid cartilage repairs, 4 cricoid cartilage repairs, and 10 tracheal repairs. CONCLUSION: The role of the deployed otolaryngologist in traumatic airway management was crucial. Our recommended treatment algorithm should optimize future traumatic airway management by stratifying traumatic airways into red (airway less than 5 minutes), yellow (airway less than 12 hours), and green categories (airway greater than 12 hours).
Head and Neck Surgery Activin A Expression Associated with Poor Prognosis in OSCC
Kai-Ping Chang, MD, PhD (presenter) OBJECTIVE: Both activin A, a member of transforming growth factor beta superfamily, and its inhibitor follistatin have been shown to be overexpressed in various cancers. We examined the potential role of activin A and follistatin in tissue and blood samples from patients with oral squamous cell carcinoma. METHOD: For activin A and follistatin, the expression of tissue samples from 92 patients was examined by immunohistochemical study and the serum levels of blood samples from 111 patients and 91 healthy controls were measurement by enzyme-linked immunosorbent assay.
RESULTS:
We found that overexpression of immunohistochemically detected activin A was correlated with positive N stage, poor histological differentiation, and perineural invasion (P ϭ 0.029, 0.002, and 0.014, respectively). In survival analyses, patients with oral squamous cell carcinoma whose tumors overexpressed activin A had a worse prognosis for overall survival and disease-free survival (P ϭ 0.009 and 0.007). However, expression of follistatin in tumor was not correlated with overall survival or disease-free survival. Serum activin A and follistatin levels in 111 untreated patients were neither significantly different from those of 91 control samples nor associated with any clinicopathological manifestations. In vitro suppression of activin A expression in OC3 cells using specific
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